The team wants to create NK cell therapies from induced pluripotent stem cells and aims to achieve proof-of-concept for their technology in multiple myeloma.
The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.
A NorthShore University HealthSystem and Color pilot picked up pathogenic variants in nearly 9 percent of unselected individuals with a hereditary cancer gene test.
